These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 3617000)

  • 21. [Eighth French Drug Surveillance Seminar. Paris, 23-24 October 1986].
    Therapie; 1987; 42(4):331-410. PubMed ID: 3686465
    [No Abstract]   [Full Text] [Related]  

  • 22. [Chemical surveillance in the industrial environment].
    Conso F
    Rev Prat; 1987 Apr; 37(23):1321-5. PubMed ID: 3602879
    [No Abstract]   [Full Text] [Related]  

  • 23. [Is imputation in drug surveillance reliable?].
    Girard M
    Therapie; 1984; 39(3):291-6. PubMed ID: 6463954
    [No Abstract]   [Full Text] [Related]  

  • 24. [Cost/benefit analysis of a regional drug surveillance center].
    Mignot G; Chichmanian RM; Spreux A; Bernard G
    Therapie; 1988; 43(5):377-8. PubMed ID: 3147546
    [No Abstract]   [Full Text] [Related]  

  • 25. [6th French seminar on drug surveillance. Clermont-Ferrand, 22-23 November 1984].
    Therapie; 1985; 40(5):287-376. PubMed ID: 4095682
    [No Abstract]   [Full Text] [Related]  

  • 26. Adverse drug reactions.
    Turner P
    Hum Toxicol; 1986 May; 5(3):161-2. PubMed ID: 3710492
    [No Abstract]   [Full Text] [Related]  

  • 27. [Drug by drug imputation of adverse effects in drug monitoring. Attempted comparison of different methods].
    Lagier G; Vincens M; Lefebure B; Frelon JH
    Therapie; 1983; 38(3):295-302. PubMed ID: 6612666
    [No Abstract]   [Full Text] [Related]  

  • 28. [Necessity and difficulties of quantitative drug monitoring].
    Lagier G; Dally S; Vincens M; Castot A
    Therapie; 1983; 38(3):319-23. PubMed ID: 6612668
    [No Abstract]   [Full Text] [Related]  

  • 29. Possible strategies for early recognition of potential drug safety problems.
    Venulet J
    Adverse Drug React Acute Poisoning Rev; 1988; 7(1):39-47. PubMed ID: 3389236
    [No Abstract]   [Full Text] [Related]  

  • 30. [Imputability in drug monitoring. Principles of the balanced drug reaction assessment method and principal errors to avoid].
    Lagier G; Vincens M; Castot A
    Therapie; 1983; 38(3):303-18. PubMed ID: 6612667
    [No Abstract]   [Full Text] [Related]  

  • 31. [Critical analysis of the adverse effects reported to the Paris-Fernand Widal Drug Monitoring Center in a 2-month period].
    Castot A; Carlier P; Lagier G; Elmalem J; Vincens M; Efthymiou M
    Therapie; 1986; 41(5):375-7. PubMed ID: 3810528
    [No Abstract]   [Full Text] [Related]  

  • 32. [Minimal information that should be found in reports about suspected adverse reactions of drugs].
    Laporte JR; Lience E
    Med Clin (Barc); 1991 Jun; 97(2):56-7. PubMed ID: 1895784
    [No Abstract]   [Full Text] [Related]  

  • 33. [Adverse effects of drugs in old people. Evaluation of cases received for a year at the French Association of Drug Monitoring Centers].
    Lavarenne J; Dumas R; Cayrol C
    Therapie; 1983; 38(5):485-93. PubMed ID: 6670071
    [No Abstract]   [Full Text] [Related]  

  • 34. Collection and analysis of drug safety data in pregnancy.
    Moretti M
    Can J Clin Pharmacol; 2007; 14(1):e34-6. PubMed ID: 17213508
    [No Abstract]   [Full Text] [Related]  

  • 35. Revised ADR report permits internal review of drug experience.
    Jeffrey LP
    Pharm Times; 1986 Dec; 52(12):48-50. PubMed ID: 10317827
    [No Abstract]   [Full Text] [Related]  

  • 36. Validation studies of drug exposures in pregnant women.
    Czeizel AE; Petik D; Vargha P
    Pharmacoepidemiol Drug Saf; 2003; 12(5):409-16. PubMed ID: 12899117
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [A network of regional correspondents for studying undesirable effects].
    Haramburu F; Péré JC; Begaud B; Albin H
    Therapie; 1985; 40(5):321-4. PubMed ID: 4095688
    [No Abstract]   [Full Text] [Related]  

  • 38. Opening Pandora's pillbox: using modern information tools to improve drug safety.
    Gottlieb S
    Health Aff (Millwood); 2005; 24(4):938-48. PubMed ID: 16012136
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [When can the cases of toxic or adverse effects of drugs be rejected? 80 cases].
    Lagier G; Castot A; Sabouraud S; de Cremoux P; Efthymiou ML
    Therapie; 1990; 45(5):435-6. PubMed ID: 2260040
    [No Abstract]   [Full Text] [Related]  

  • 40. Assessing risk in postmarketing surveillance.
    Cerrito PB; Cerrito JC
    J Biopharm Stat; 1991; 1(2):221-35. PubMed ID: 1844698
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.